Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-06-30

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of escitalopram (30 mg/day) in two parallel groups (randomization ratio, escitalopram 2/placebo 1).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder

NCT02191397

Depressive Disorder, Major

COMPLETED PHASE3

Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

NCT00220701

Dysthymic Disorder

COMPLETED PHASE4

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

NCT00109044

Major Depressive Disorder

COMPLETED PHASE3

Study of Escitalopram in Adult Patients With Major Depressive Disorder

NCT00108979

Major Depressive Disorder

COMPLETED PHASE3

Escitalopram in Adult Patients With Major Depressive Disorder

NCT00668525

Major Depressive Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective: to evaluate the efficacy of oral escitalopram at the dosage of 30 mg/day for 16 weeks on the 6-minute walking test in patients with pulmonary hypertension.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Group Type ACTIVE_COMPARATOR

escitalopram

Intervention Type DRUG

escitalopram

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

escitalopram

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects who meet all the criteria listed below will be considered for study inclusion:

* Male or female older than 18 years of age
* Meeting World Health Organization (WHO) criteria for pulmonary hypertension (mean pulmonary arterial pressure \[PAP\] \> 25 mmHg at rest and pulmonary capillary wedge pressure \< 15 mmHg during right heart catheterization):

* primary pulmonary hypertension (sporadic or familial), or
* pulmonary hypertension associated with connective tissue diseases, or
* pulmonary hypertension associated with HIV infection, or
* pulmonary hypertension associated with use of appetite suppressants or other toxic compounds, or
* pulmonary hypertension associated with shunting through a congenital heart defect surgically treated
* Class II or III in the NYHA classification scheme
* With a 6-minute walking test distance between 40% and 80% of theoretical values (approximately 50 and 480 m)
* On conventional treatment, with no change in this treatment during the last month preceding the study. Conventional treatment includes calcium antagonists or beraprost.
* Subject who consents to participate in the study.

Exclusion Criteria

Subjects with any of the following clinical features will not be included in the study:

* Pulmonary hypertension related to aortic or mitral valve disease, or extrinsic pulmonary vein compression
* Pulmonary hypertension related to hypoxia from respiratory disease with a total lung capacity \< 70% or Tiffeneau index \< 60% upon testing within the last 6 months (chronic obstructive lung disease, interstitial disease, sleep apnea syndrome, alveolar hypoventilation, chronic exposure to high altitudes, neonatal lung disease, or alveolar capillary dysplasia)
* Pulmonary hypertension associated with portal hypertension
* Pulmonary hypertension secondary to chronic thrombosis and/or embolism (occlusion of the proximal or distal pulmonary arteries by thrombosis)
* In the 6-minute walking test, inability to walk for 6 minutes, for any reason, or walking distance of less than 50 m
* Pregnancy, lactation, women of childbearing potential (if needed, effective contraception will be prescribed)
* History of hypersensitivity to citalopram or to medications structurally related to citalopram
* Treatment with another investigational drug within the 3 months preceding study inclusion
* Cardiovascular, hepatic, neurological or endocrine disease that is clinically significant, or any other significant disease that may interfere with the study protocol or with the interpretation of study findings
* History of drug or alcohol abuse
* Liver failure (except abnormalities related to the right ventricular failure)
* Kidney failure
* Mental status preventing the patient from understanding the nature, objectives, and possible consequences of the study
* Non stabilized psychiatric disorders
* Subject unable to comply with protocol-related constraints (e.g., uncooperative, unable to attend follow-up visits, and probably unable to complete the study).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No